ReviewEuropean journal of haematology2026
Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.
Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions from clinical trials.British journal of haematology · 2026Article
- Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.Blood advances · 2026Review
- Geriatric Assessment in Patients Aged 70 Years and Older Considered for CAR T-Cell Therapy: A Retrospective Study.Cancers · 2026Article
- Review
- Quality of Life in CAR-T Cell Therapy.Hematology reports · 2026Review
- Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.European journal of haematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesFrailty is a key consideration in determining whether a patient is robust enough for CAR T-cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T-cell therapy and its potential impact on their eligibility.
methodsFollowing the Joanna Briggs Institute guidelines, we adopted a scoping review methodology. Our search was conducted across the databases CINAHL, Cochrane, Embase, Medline, PubMed, Google Scholar, clinicaltrials.gov, clinical trials register.eu, and euclinicaltrials.eu for studies published from 2017 to March 2nd 2024. Studies were screened by independent teams of reviewers using the web application Rayyan.
resultsOur review included 12 studies, with varied study designs. No study in a pediatric CAR T-cell setting was found. A wide variation in assessing frailty before CAR T-cell therapy was evident, with ECOG being the most frequently used assessment tool.
conclusionsAn appropriate frailty assessment before CAR T-cell therapy promotes the productive use of resources and proper patient selection. Using a geriatric assessment and incorporating an assessment tool such as the CAR HEMATOTOX has the potential for assessing frail CAR T-cell therapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.